Preliminary findings from new research published in the journal Obstetrics and Gynecologyindicate that the 52-mg levonorgestrel intrauterine device (IUD) and the one-rod contraceptive implant containing etonogestrel both continue to be highly effective for an additional year beyond the durations of effectiveness approved by the U.S. Food and Drug Administration. The levonorgestrel IUD is currently approved for 5 years of use and the etonogestrel implant is approved for 3 years of use.
The data published represent preliminary findings from an ongoing study led by researchers at the Washington University School of Medicine in St. Louis.
The abstract is available from the journal website here.
Comments